BRCA1 and neoplasm: MI includes tumor origin (e.g. breast) clinical setting (neoadjuvant, adjuvant, metastatic), age at collection, pathological diagnosis (with H&E staining), tumor grade and stage, clinically relevant biomarker expression (e.g. estrogen and progesterone receptors (ER/PR) and ErbB2 (HER2) amplification and/or overexpression, as well as BRCA1/2 germline mutation status in the case of breast cancer), therapeutic treatments and associated responses, metastatic sites in the patient, as well as patient demographic information including age at diagnosis, race, ethnicity, and vital status.